Truist Reiterates Buy Rating on Genmab A/S (GMAB) Following MRUS Bid
Tweet Send to a Friend
Truist Securities analyst Asthika Goonewardene reiterated a Buy rating and $46.00 price target on Genmab A/S (NASDAQ: GMAB).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
